CARY, N.C., Nov. 21, 2016 -- As part of its recently announced strategy to become a leader in high-value, high-growth specialty market segments in the crop protection industry, Arysta LifeScience has placed biosolutions at the center of its focus. Executing on this strategy, the company recently signed an agreement with Beem Biologics, Inc., in which Arysta LifeScience will license a new, novel, plant extract-derived biostimulant technology from Beem Biologics. The strategic alliance between the two companies will further expand Arysta LifeScience’s leading product portfolio in the fast-growing segment for plant stress management and stimulation.
“With this agreement, Arysta LifeScience reaffirms its position as a global leader in biostimulants, representing an important step in the execution of our new strategy,” said Diego Lopez Casanello, President, Arysta LifeScience.
“The alliance with Arysta LifeScience represents a milestone in our mission to become a premium provider of biological technologies to growers around the world,” added Stephen Butler, CEO of Beem Biologics.
The announcement of the agreement came a few days after Arysta LifeScience reported its third-quarter results, noting that biosolutions sales have contributed meaningfully to the company’s overall performance in 2016. The companies did not disclose the terms of the agreement.
A Novel, New Plant Extract
The proprietary biostimulant being licensed by Arysta LifeScience is a natural biological complex that reduces the impact of stress on the growing crop while promoting vigorous and healthy plant growth. “Field trials through university, private research firms and in-house studies over the past 24 months confirm this new biostimulant significantly promotes healthy yet rapid early plant development, enhanced flowering, fruiting and higher yields in a wide range of crops,” said Lance Beem, Inventor & Consultant.
Arysta LifeScience has licensed exclusive global rights to the proprietary technology for uses in agricultural markets all around the world. The parties intend to collaborate to develop and commercialize new formulations and uses of the technology.
“This exciting, new and unique biostimulant works well in combination with conventional crop protection products and will be a valuable new tool that we can offer to growers who are adopting sustainable agricultural practices,” explained Neil Stapensea, Global Head, Biostimulants & Innovative Nutrition Product Management, Arysta LifeScience.
About Arysta LifeScience
Arysta LifeScience is a global agricultural company specializing in the marketing and distribution of innovative crop protection and life science brands. With more than 200 active ingredients, Arysta LifeScience has a well-integrated biological and chemical portfolio to provide complete solutions to growers. The company’s wide range of offerings includes biosolutions, fungicides, herbicides, insecticides and seed treatments. Arysta LifeScience, which has more than 4,000 employees working in over 100 countries to serve customers worldwide, had 2015 revenues of US$1.8 billion. Arysta LifeScience is owned by Platform Specialty Products (www.platformspecialtyproducts.com), a global innovator of technologically advanced specialty chemical products and provider of technical services. For more information on Arysta LifeScience, visit www.arystalifescience.com.
About Beem Biologics
Beem Biologics, Inc (www.beembiologics.com) is a product developer and manufacturer of biological compounds for the crop protection industry. Through discovery, product development and trials, BBI developed isoprenoid compounds (“ISO-Extracts™”) derived from desert, mountain and sea plants that are highly effective, economical to use, and have broad application in various formulations for fertilizer, stimulant and pesticides.
Media Contact: Carey Dorman Director – Corporate Development Platform Specialty Products Corporation 1-561-406-8465


Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 



